|
|
|
12.06.25 - 18:06
|
Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025 (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2025.
Month
Date
Total number of outstanding shares
Total number of theoretical voting rights (1)
Total number of exercisable voting rights (2)
May
05/31/2025
18,087,690
20,213,633
20,168,948
(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Arti...
|
|
|
15.05.25 - 18:03
|
Number of Shares and Voting Rights of ADOCIA as of April 30th, 2025 (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of April 30th, 2025.
Month
Date
Total number of outstanding shares
Total number of theoretical voting rights (1)
Total number of exercisable voting rights (2)
April
04/30/2025
18,087,690
20,223,333
20,181,801
(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 22...
|
|
|
14.05.25 - 18:06
|
ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
|
|
|
Cash position of €12.2 million as of March 31, 2025, including €9.7m from the private placement successfully completed in February 2025
Cash runway extended until Q2 2026
Top-line data from Phase 3 BioChaperone® Lispro studies in China on track for mid-2025 readout to be followed by submission for Chinese regulatory review in 2025
Business priority for 2025 remains establishing partnerships for M1Pram with Sanofi and for BioChaperone® CagriSema
New AdoShell® data presentations at scientific conferences showcase potential curative treatment for Type 1 Diabetes
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2025 and provides a business update.
“Our strategic priority remains securing partnerships for BioChaperone...
|
|
|
30.04.25 - 18:03
|
ADOCIA Announces the Release of its Universal Registration Document for the Year 2024 (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today the filing of its 2024 Universal Registration Document with the “Autorité des marchés financiers” (AMF - the French financial markets regulator) on April 29th, 2025.
An electronic copy of this document is available on the company's website (www.adocia.com) as well as on the website of the AMF (www.amf-france.org). Hard copies are available upon request at the company's headquarters located 115, avenue Lacassagne, 69003 Lyon.
The following documents are included in the Universal Registration Document (document d'enregistrement universel):
the 2024 annual financial report, which includes the 2024 Management Report,
the 2024 Board of Directors' report on corporate governance,
the reports from the statutory auditors and ...
|
|
|
17.04.25 - 18:03
|
ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update (Business Wire)
|
|
|
Cash position of €7.5m (million) as of December 31, 2024, including:
€2m received from private placement in March 2024
€9.8m from an equity financing line (“PACEO”) with Vester Finance
Cash runway extended until Q2 2026, including €9.7m from the private placement completed in February 2025 and a $10m milestone payment from partner Tonghua Dongbao expected at the end of Q2 2025
Advances with our flagship projects:
BioChaperone® Lispro final dosing of Phase 3 studies in China, with top-line data expected in mid-2025 and submission for Chinese regulatory review in 2025
Business priority to partner BioChaperone® CagriSema (stable combination of cagrilintide and semaglutide) and M1Pram, covered by a still-ongoing exclusivity agreement with Sanofi and a Phase 2b clinical program in preparation
Continued development of AdoShell® platform with plans to submit clinical trial application to the regulator in 2025
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Adocia (Euronext Paris: FR00111...
|
|
|
11.04.25 - 18:06
|
Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025 (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”), ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of March 31st, 2025.
Month
Date
Total number of outstanding shares
Total number of theoretical voting rights (1)
Total number of exercisable voting rights (2)
March
03/31/2025
18,084,200
20,219,839
20,176,736
(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-1...
|
|
|
14.03.25 - 18:06
|
Number of Shares and Voting Rights of ADOCIA as of February 28th, 2025 (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of February 28th, 2025.
Month
Date
Total number of outstanding shares*
Total number of theoretical voting rights (1)
Total number of exercisable voting rights (2)
February
02/28/2025
18,084,200
20,218,939
20,187,490
* 120,000 new shares have been issued over the month in connection with the PACEO financing line, whose main characteristics are described i...
|
|
|
28.02.25 - 19:30
|
ADOCIA Announces the Settlement-Delivery of its €9.7 Million Private Placement (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
Adocia (Euronext Paris : FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), announces today the successful settlement and delivery of its private placement amounting €9,732,500 (issue premium included) carried out through the issuance, without preferential subscription rights, of 2,125,000 new ordinary shares of the Company (the “New Shares”), each with one share warrant attached (a “BSA”), which has been announced on February 26, 20251.
The New Shares have been admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0011184241-ADOC.
The BSAs, which have been immediately detached (détachés) from the New Shares upon issuance, are...
|
|
|
|
|
26.02.25 - 08:45
|
ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026 (Business Wire)
|
|
|
Capital increase of a total amount of €9.7 million in gross proceeds by issuing a total number of 2,125,000 new shares, each with one share warrant attached, at €4.58 per share
Gross Proceeds include €0.5 million from Gerard Soula, chairman of the Board and co-founder of the Company, €0.9 million from Vester Finance, an historical investor, €7 million from Armistice Capital and €1.3 million from a limited number of investors
Settlement-delivery of the new shares and share warrants expected on February 28, 2025
LYON, France--(BUSINESS WIRE)--Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
Adocia (Euronext Paris : FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), announces today the successful completion of a capital increase of a total gross amount of €...
|
|
|
25.02.25 - 19:06
|
ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
|
|
|
Cash position of €7.5 million as of December 31, 2024
BioChaperone® Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025
Ongoing partnership discussions on M1Pram with Sanofi and business priority to partner the stable combination of cagrilintide and semaglutide (CagriSema) using the BioChaperone® platform
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), reports financial results for the fourth quarter of 2024 and provides a business update.
“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide enabled by our BioChaperone technology—and the compl...
|
|
|
22.01.25 - 18:03
|
ADOCIA Announces Half-Year Report on Adocia′s Liquidity Agreement with Kepler Capital Markets (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31, 2024:
Number of shares: 31,516
Cash balance of the liquidity account: € 96,275.08
During the 2nd half of 2024, a total of:
Buy-side
240,922 shares
€ 1,679,613.48
1,424 transactions
Sell-side
219,735 shares
€ 1,565,816.25
1,275 transactions
The following resources appeared on the last half year statement on June 30, 2024 on the liquidity account:
Number of shares: 10,329
Cash balance of the liquidity account: € 208,460.92
The following resources appeared on the liquidity account when the activity started:
Number of shares: 15,026
Cash balance of the liquidity account: € 300,000.00
The liquidity agreement complies with AMF Decision n° 2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market prac...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
